Overview

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Status:
Completed

Trial end date:
2009-08-28

Target enrollment:

Participant gender:

Summary

This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with fixed Humulin R or Humalog doses in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc